Nov 17, 2026
FDA approves Roche's giredestrant pill for advanced breast cancer
The FDA approved Roche's oral SERD giredestrant in combination with Novartis's everolimus for advanced or metastatic breast cancer, reducing risk of progression or death by 62%. This marks Roche's entry into the competitive SERD market.
3 sources
00